chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient states 2 hrs after receiving vaccine-she was dizzy, fainted, fell to the floor and had to call the rescue squad to help her up. She vomited and has not felt right since.
Fever chills and loss of energy. Have never recovered energy. Sever nasal issues with drying of nasal passages ,  headaches and  on going vertigo. All Unresolved
pt recv varivax in 7/95 & in 5/98 pt exp ``classic varicella'' w/more than 50 lesions. rpt nurse noted pt afeb
Information has been received from a 78 year old female consumer with PENICILLIN allergy who in approximately January 2009, was vaccinated with 0.65 ml of a dose of ZOSTAVAX (Merck) intramuscularly. Concomitant medications include heart medication, diabetes medication and for "everything" (unspecified medications). Within a week of the vaccination, the consumer reported that the skin "in my groin area" and on her chest "white, hard and rough". The consumer sought unspecified medical attention. The consumer did not want a follow up with her doctor. No further information is available.
0900:  Patient was administered Moderna   in right deltoid,  patient was moved over to observation seat in vaccination room for close monitoring.  0901: Patient reported feeling flushed, redness to face and cheeks, and reporting lower back pain. RN assessed onsite, patient remains alert, oriented. Patient vitals taken : 114/ HR 66, RR 18, 99% on RA, 98.4. Nursing staff elevated legs and provided Benadryl orally for possible allergic reaction to medications and provided ice pack. .   0906: Pt reported that symptoms were resolving, no longer feeling flushed, skin color and touch back to baseline. Patient remained with staff for 30 min for observation , husband remains at side. patient remains alert and oriented, smiling.
Information has been received from a healthcare worker referring to an unspecified number of patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of M-M-R II (lot # L043703, expiration date 03-NOV-2017, dose and route not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected as there was no consent to contact the physician.
noticed red spots then rash on groin area spreading to upper trunk and bilateral arms, with itching 11 days after receiving the flu vaccine for the first time
bullous pemphigoid; itchy blisters on my skin; itchy blisters on my skin; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 18Nov2021 at 09:00 as dose 3 (booster), single (Lot number: FH8028) at the age of 46 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, single, Unknown Manufacturer), for COVID-19 Immunization; Covid-19 vaccine (Dose 2, single, Unknown Manufacturer), for COVID-19 Immunization. The following information was reported: PEMPHIGOID (medically significant), outcome "not recovered", described as "bullous pemphigoid"; PRURITUS (non-serious), BLISTER (non-serious), outcome "not recovered" and all described as "itchy blisters on my skin". The events "bullous pemphigoid" and "itchy blisters on my skin" required physician office visit. Therapeutic measures were taken as a result of pemphigoid, pruritus, blister.  Additional information: the patient received the 4th dose of Pfizer Covid-19 vaccine on 11Nov2022 at 11:00 AM in the left arm. Within a week or two of the bivalent booster she developed itchy blisters on her skin similar to what happened after her last booster dose (Dose 3). It was reported that after the first incident, it was diagnosed by a dermatologist as bullous pemphigoid, patient was given oral and topical steroid and it improved. The blisters begin as itchy and if she scratched them they would pop and turn into a scab to heal. Patient have never had any of these symptoms before receiving the covid vaccine. The patient has no known allergies.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300119722 same patient/events different vaccine doses;US-PFIZER INC-202300120267 same patient, different vaccine doses/events;
About 12 hours after receiving vaccine the left arm was immobile. Could not lift or move the arm without use of the right arm. There was severe pain in the shoulder joint. One month after the vaccine the left shoulder joint remains painfully impinged and has decreased mobility
the vial undergo any temperature excursions; Vaccine was placed in refrigerator on 20-Jan-2022, expired product date on 20-Jan-2022, administration date on 12-May-2022; 13 patients received  an expired vaccine for a booster dose; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose), PRODUCT TEMPERATURE EXCURSION ISSUE (the vial undergo any temperature excursions) and PRODUCT STORAGE ERROR (Vaccine was placed in refrigerator on 20-Jan-2022, expired product date on 20-Jan-2022, administration date on 12-May-2022) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045L21A and 038B21A) for COVID-19 vaccination.     Patient didn't had past medical history and allergy information reported as unknown. Patient ever had COVID + test or diagnosis reported as unknown. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-May-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (the vial undergo any temperature excursions) and PRODUCT STORAGE ERROR (Vaccine was placed in refrigerator on 20-Jan-2022, expired product date on 20-Jan-2022, administration date on 12-May-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose), PRODUCT TEMPERATURE EXCURSION ISSUE (the vial undergo any temperature excursions) and PRODUCT STORAGE ERROR (Vaccine was placed in refrigerator on 20-Jan-2022, expired product date on 20-Jan-2022, administration date on 12-May-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  The temperature excursion details of vaccine reported as maximum or minimum temperatures reached 44.6°F and 38.8°F and excursion duration was 3 months.  The treatment information was not provided.
Tinnitus.; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 27-year-old) as a single dose for COVID-19immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date the patient experienced tinnitus. The patient reported that it had ruined his life. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever; This case was reported by a consumer and described the occurrence of fever in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th March 2021, the patient received the 1st dose of Shingrix. In March 2021, less than a week after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was not recovered/not resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows: The case was reported by patient's wife. On the day before reporting date, the patient had received first dose of Shingrix and experienced fever. The reporter inquired that weather they should contact the doctor.  No other information was reported.
Two days post vaccination, patient noticed redness  and swelling at injection site.  Then on day 7 post-vaccination, redness and swelling spread and itching began.  Redness and swelling continued to spred from day 7-10.  Patient saw her primary care physician who diagnosed it as a localized allergic reaction.  They prescribed benedryl, Claritin and doxycycline.
This spontaneous report was received from a healthcare worker refers to a patient of unknown age and gender. On 23-JAN-2008, the patient was vaccinated with first dose of VAQTA (lot #, expiry not reported), 0.5 ml, intramuscularly. On 07-JUL-2008, the patient was vaccinated with dose 2 of VAQTA (lot #, expiry not reported), 0.5 ml intramuscularly. No adverse effect reported. Additional information has been requested.
This case was reported by a pharmacist via call center representative and described the occurrence of erythema of extremities in a 75-year-old female patient who received Shingrix (batch number 3NY5G, expiry date 8th March 2021) for prophylaxis. On 4th October 2018, the patient received Shingrix (intramuscular). In October 2018, less than a month after receiving Shingrix, the patient experienced erythema of extremities and pain in arm. On an unknown date, the outcome of the erythema of extremities and pain in arm were not recovered/not resolved. It was unknown if the reporter considered the erythema of extremities and pain in arm to be related to Shingrix. Additional details were reported as follows: The patient received a dose of Shingrix on the left deltoid. On 11th October 2018, the patient stated that, she experienced redness and soreness on her arm. The reporter was not sure when the adverse events were started. The reported lot number (3NY56) for Shingrix did not exist and was updated to 3NY5G, according to sales datasheet.
Warmth, redness, tenderness extending 4 cm from injection site at maximum, with persistent 1cm erythema & rash 2 plus weeks post injection.
I received the second dose of the Moderna COVID-19 vaccine on 1/27/21 at 07:30 a.m.. Around 11:30 p.m. I developed a throbbing headache, chills, and severe muscle and joint pain. Throughout the night I developed dizziness, crushing chest pain and my left ear felt plugged. In the morning, I was up walking and started to not feel right due to the dizziness and fainted. After 6 days of feeling this way, I contacted my PCP and had a virtual visit. I was given a step down dose of Prednisone and a medication for the dizziness. My PCP advised me that I needed to report my reaction to this vaccine to the CDC. I contacted my Manager and also had to contact the nurse here.
bad shingles right after their boosters; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, immediately after receiving Shingles vaccine, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.     Additional Information: GSK receipt date: 27-Feb-2023 Reporter's comment: The case was received from the consumer via interactive digital media. The reporter asked that mRNA jab. The reporter knew that the patient got bad shingles right after the boosters. Additional supportive information: The follow-up could not be possible as no contact details were available. As per reported information it seems that reporter was reporting about the 2nd dose of Shingles vaccine which was considered as booster of shingles vaccine, therefore single suspect was coded with dose number 2 with immediate time to onset for shingles. This 1 of 3 linked cases reported by same reporter.; Sender's Comments:  US-GSK-US2023AMR036625:Same reporter
Continuous crying 1230-630AM; MD called advised to continue APAP for 2 days; give ped DT;
Swelling, redness, pain, and itching over 24-48 hour period.
This spontaneous report as received from a certified medical assistant (CMA) refers to a patient of unknown age. On an unknown date the patient was vaccinated with PNEUMOVAX 23 (dose, route and lot# not reported) that was exposed to temperatures outside of the proper storage range. There was no adverse effect. This is one of the four reports from the same reporter. (Linked to 1411USA002768, 1411USA002891 and 1411USA002892). Additional information has been requested.
19JAN99 phone  parent stated child had pain in arms, legs, & neck;this started 11JAn99 & has gotten progressive worse;child heard in background moaning;parent did not know if temp was elevated said child felt hot;instructed to go to MD;
PC 10/7/15 -> pinpoint red rash all over, yellow eye discharge - appt for next morning, give TYLENOL/MOTRIN for fever, discomfort, BENADRYL for hs. OV 10/8/15 -> dx with viral exanthem vs MMR reaction - supportive care. PC 10/9/15 -> still crying, fussy, rash but no fever - to give pain reliever - rash will fade and to call if present after 3-4 days - poss. Fifth's disease. 10/10 OV - rash fading - viral exanthem dx. PC 10/12 - hives developed, eyes swollen with discharge. Sent for stat BW.
This spontaneous report was received from a consumer regarding her three child sons of unknown age. The patients' pertinent medical history, concurrent conditions, concomitant therapies, drug reactions or allergies were not reported. On unspecified dates, the patients were vaccinated with the first and second doses of GARDASIL 9 (dose, route, anatomical location, lot # and expiration date were unspecified for both vaccines). On an unknown date, the patients were vaccinated with the third dose of GARDASIL 9, Lot # reported as L040459 (dose, route, anatomical location, and expiration date were unspecified). Following the third administration of the third dose, the reporter received a letter from her children's physician stating that all the three last doses of GARDASIL 9 that were administered to her three sons were improperly stored. No adverse effects were reported. This is one of two cases received from the same reporter. Additional information is not expected because no contact information was provided.
Information has been received from a health professional, via a company representative, concerning the health professional's 15 year old daughter, who was vaccinated with the first dose (date unspecified), the second dose (date unspecified) and the third dose (date unspecified) of Gardasil. The mother stated that her daughter had arm soreness in the area of the injection site following each vaccination; the arm soreness lasted for approximately one week and then resolved. It was unknown if the patient sought medical attention. No further information is expected.
This spontaneous report as received from a physician via a company representative refers to a 2 year old male patient. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapy were not reported. On 09-OCT-2018, 2 year old male patient was inadvertently vaccinated with GARDASIL 9 (dose, frequency, lot #, expiry date and route were not reported) for prophylaxis (drug administered to patient of inappropriate age). No adverse effects were reported. No product quality complaint was involved.
Pharmacy technician called the RXM at home and reported that the pharmacist on duty had given the patient a Covid-19 vaccine on 07/05/2021 from a vial that was punctured on 07/03/2021 at approximately 11:30. The punctured vial was stored in the refrigerator for the entire time after puncture however it does not meet the CDC temperature storage guidelines of discarding any unused vaccine after 12 hours of puncture.
case of Nephrotic Syndrome - symptoms first appeared 2-3 days after the vaccine (also had previous asymptomatic COVID-19 positive test)
Approximately 1 min after receiving vaccine, patient became diaphoretic, pale & stated he did not feel well. He lost consciousness & was lowered to the floor. No SOB, angioedema or generalized rash. EMS evaluated & transported patient to ER. Discharged from ER with diagnosis of vaso-vagal episode.
This is a spontaneous report from a contactable physician via Pfizer sales representative. A female adolescent patient received TRUMENBA (lot S26962) via an unspecified route of administration on an unspecified date at single dose for immunisation. The patient medical history and patient's concomitant medications were not reported. The patient fainted and sent to the ER for fluids on an unspecified date. The outcome of the event was unknown. Sender's Comments: The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, as appropriate. The case will be reassessed if additional information becomes available.
Small satellite erythematous papules throughout both arms, back, chest, right wrist and right foot.
I experienced quite mild symptoms when I had my breakthrough case. They were cold-like symptoms, like a sore throat and a runny nose. At one point, I started to feel a chill, and that was when I realized it wasn't a cold. I took my temperature, which was a little higher than usual, but not too high. It was a while before I took a home antigen test, because on account of the mildness of the symptoms, it didn't occur to me that I might have had COVID-19. It was about the fourth day of my illness before I took a home test and got a positive result. I ended up taking about six home tests during my illness. They all yielded positive results until 12/31/2022, which was when I finally got a negative result for the first time.
Pt presented at 12:40pm with facial rash. No diagnosis at this time but advised to contact if symptoms persist.
occasionally feels achy almost like she has the flu; occasionally feels achy almost like she has the flu/occasionally has muscle pain in her right arm around to her back; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (occasionally feels achy almost like she has the flu) and MYALGIA (occasionally feels achy almost like she has the flu/occasionally has muscle pain in her right arm around to her back) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INFLUENZA (occasionally feels achy almost like she has the flu) and MYALGIA (occasionally feels achy almost like she has the flu/occasionally has muscle pain in her right arm around to her back). At the time of the report, INFLUENZA (occasionally feels achy almost like she has the flu) and MYALGIA (occasionally feels achy almost like she has the flu/occasionally has muscle pain in her right arm around to her back) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications  was reported. No treatment was reported.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant medication use were not provided. On or about 20-JAN-2015, the patient was vaccinated with ZOSTAVAX (dose, route of administration, site of administration and lot # were not provided) for its intended purpose: the prevention of shingles. As a direct result of the vaccine, the patient suffered from a shingles outbreak, in addition to chronic pain, rash and lesions to various parts of his (Conflicting information, as patient's first name is a female name) body. The patient did not have a shingles outbreak until 02-FEB-2017. As a direct result of the vaccine, the patient suffered mental and emotional distress due to resulting physical limitations and seriousness of his (Conflicting information) condition. As a result of ZOSTAVAX vaccine, the patient sustained severe and permanent personal injuries. Further, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. The patient has incurred medical expenses and other economic harm as a direct result of use of ZOSTAVAX. The reporter considered the shingles outbreak to be related to ZOSTAVAX. The event of Shingles outbreak was considered to be disabling. Additional information has been requested.
Pt has a PMH of chronic systolic CHF with CKD stage III. He presented to the ED for chest pain, a nonproductive cough and exertional dyspnea. He was admitted due to an NSTEMI and acute hypoxic respiratory failure secondary to COVID pneumonia.
PATIENT STATED BEING WEAK AND DIZZY 5 MINUTES AFTER VACCINE ADMINISTRATION. PHARMACIST(RPH) RECOGNIZED PATIENT'S DECLINING STATUS, OBTAINED EPI-PEN (0.3MG IM DOSE).  ONCE THE RPH WAS BACK TO THE PATIENT (~5 SECONDS), THE PATIENT HAD PASSED OUT. RPH ADMINISTERED EPI-PEN IM ON LEFT THIGH. PATIENT REGAINED CONSCIOUSNESS  AFTER 15 SECONDS. EMS ARRIVED WITHIN 15 MINUTES AND TOOK PATIENT TO HOSPITAL.
Starting 3 days after the vaccine, I developed a headache located on the right side of my head which lasted for about 2-3 months. Also, I had a pressure behind my right eye associated with the headache. When the headache dissipated, I developed a ringing in my ears which lasted for about 2-3 months. One day at a party, I noticed the ringing stopped (but never came back) and that's when I broke out into a sweat and felt extremely dizzy. I was rushed to the ER where they did lots of blood work and did an angiogram and angioplasty to open up some blood vessels around my heart (due to blockage). They hospitalized me for 3 days and wanted to transfer me to another hospital to do major open heart surgery, but I declined due to being opposed to it. I got a second opinion from my PCP who referred me to the cardiologist that I currently see to this day. I have been put on numerous medicines to maintain my blood pressure.
The pt received the vaccines on 4/13/00 in the left deltoid. The pt states both deltoids sore that PM and next day. Noticed swelling of right injection site on 4/14/00. Then noticed bruising below injection site on 4/17/00. Area approximately 2 x 4 inches on right bicep area that appears as dense petechiae. The pt did seek family physician for evaluation.